| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,067 |
22,766 |
$2.26M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,052 |
16,881 |
$1.19M |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
4,798 |
4,694 |
$279K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
12,055 |
11,687 |
$174K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,385 |
1,295 |
$104K |
| 36415 |
Collection of venous blood by venipuncture |
17,656 |
16,468 |
$93K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
4,181 |
4,052 |
$80K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
674 |
671 |
$56K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
590 |
587 |
$50K |
| 90686 |
|
5,092 |
4,975 |
$44K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
465 |
461 |
$42K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,910 |
3,815 |
$36K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,375 |
1,285 |
$35K |
| 80061 |
Lipid panel |
2,453 |
2,391 |
$32K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
417 |
411 |
$32K |
| 91320 |
|
373 |
361 |
$30K |
| T1013 |
Sign language or oral interpretive services, per 15 minutes |
559 |
504 |
$27K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,383 |
2,262 |
$20K |
| 90480 |
|
655 |
630 |
$19K |
| 86481 |
|
248 |
207 |
$19K |
| 92551 |
|
2,305 |
2,280 |
$18K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
480 |
451 |
$16K |
| 80053 |
Comprehensive metabolic panel |
1,630 |
1,527 |
$16K |
| 90715 |
|
820 |
811 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
374 |
356 |
$15K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
714 |
626 |
$15K |
| 99215 |
Prolong outpt/office vis |
108 |
105 |
$14K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
403 |
387 |
$14K |
| 0012A |
|
296 |
293 |
$13K |
| 0011A |
|
309 |
308 |
$12K |
| 85027 |
|
1,757 |
1,675 |
$11K |
| X5622 |
|
90 |
70 |
$10K |
| 90651 |
|
376 |
368 |
$10K |
| 99188 |
|
1,032 |
1,023 |
$9K |
| 90656 |
|
943 |
937 |
$9K |
| 96127 |
|
2,157 |
2,128 |
$9K |
| 90662 |
|
143 |
142 |
$8K |
| 0064A |
|
205 |
204 |
$8K |
| 84443 |
Thyroid stimulating hormone (TSH) |
478 |
472 |
$8K |
| 0002A |
|
288 |
287 |
$8K |
| 0054A |
|
167 |
167 |
$7K |
| 0001A |
|
300 |
297 |
$7K |
| 86780 |
|
580 |
526 |
$7K |
| 99000 |
|
636 |
613 |
$7K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
67 |
67 |
$7K |
| 86803 |
|
564 |
486 |
$6K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
70 |
70 |
$6K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
36 |
35 |
$5K |
| 80306 |
|
299 |
269 |
$5K |
| 81025 |
|
586 |
549 |
$5K |
| 59425 |
|
12 |
12 |
$5K |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
126 |
124 |
$5K |
| 90677 |
|
45 |
42 |
$5K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
41 |
38 |
$5K |
| 0072A |
|
112 |
111 |
$5K |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
197 |
192 |
$5K |
| 0071A |
|
109 |
103 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
117 |
115 |
$4K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
549 |
499 |
$4K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
86 |
79 |
$4K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
42 |
41 |
$4K |
| 87210 |
|
608 |
584 |
$4K |
| 87340 |
|
437 |
358 |
$3K |
| 99173 |
|
2,142 |
2,115 |
$3K |
| 0004A |
|
76 |
74 |
$3K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
390 |
344 |
$3K |
| 0031A |
|
119 |
119 |
$3K |
| 90670 |
|
422 |
421 |
$3K |
| 86706 |
|
364 |
287 |
$3K |
| 86704 |
|
275 |
212 |
$2K |
| 0052A |
|
47 |
47 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
235 |
223 |
$2K |
| 90691 |
|
15 |
15 |
$2K |
| 86708 |
|
228 |
172 |
$2K |
| 86787 |
|
203 |
160 |
$2K |
| 99385 |
|
15 |
15 |
$2K |
| 81001 |
|
465 |
448 |
$2K |
| 99442 |
|
35 |
32 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
133 |
131 |
$1K |
| 83655 |
|
107 |
106 |
$1K |
| 82043 |
|
226 |
221 |
$1K |
| 99443 |
|
14 |
12 |
$1K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
12 |
12 |
$1K |
| 85018 |
|
402 |
394 |
$1K |
| G0008 |
Administration of influenza virus vaccine |
84 |
78 |
$1K |
| 0124A |
|
27 |
25 |
$975.29 |
| 99383 |
|
12 |
12 |
$928.50 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
30 |
30 |
$904.79 |
| 90734 |
|
257 |
256 |
$821.66 |
| 96161 |
|
383 |
381 |
$711.92 |
| 90473 |
|
41 |
41 |
$618.56 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
233 |
228 |
$614.56 |
| 0051A |
|
14 |
14 |
$606.90 |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
27 |
27 |
$564.58 |
| 81003 |
|
298 |
290 |
$536.67 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
13 |
13 |
$444.96 |
| 87338 |
|
27 |
27 |
$416.04 |
| 90716 |
|
12 |
12 |
$341.36 |
| 36416 |
|
72 |
66 |
$212.39 |
| 93000 |
|
18 |
17 |
$173.09 |
| 86709 |
|
13 |
13 |
$146.25 |
| 84439 |
|
12 |
12 |
$113.74 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
255 |
251 |
$109.70 |
| 90707 |
|
27 |
27 |
$83.69 |
| 82950 |
|
13 |
12 |
$62.04 |
| 82570 |
|
12 |
12 |
$0.12 |
| 90698 |
|
251 |
250 |
$0.00 |
| 90680 |
|
100 |
100 |
$0.00 |
| 90696 |
|
25 |
25 |
$0.00 |
| 90744 |
|
133 |
131 |
$0.00 |
| 90619 |
|
12 |
12 |
$0.00 |
| 90723 |
|
48 |
48 |
$0.00 |
| 90633 |
|
222 |
221 |
$0.00 |
| 90713 |
|
31 |
27 |
$0.00 |
| 90710 |
|
28 |
26 |
$0.00 |
| 90648 |
|
60 |
60 |
$0.00 |
| 86682 |
|
21 |
15 |
$0.00 |
| 90681 |
|
13 |
13 |
$0.00 |